Vor Biopharma Inc.
NASDAQ Global SelectTotal Valuation
Vor Biopharma Inc. carries a market capitalization of 92.12M, placing it among publicly traded companies globally. Its enterprise value stands at -155.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 92.12M |
| Enterprise Value | -155.83M |
Share Statistics
Vor Biopharma Inc. currently has 54.19M shares outstanding.
| Shares Outstanding | 54.19M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.24 |
| P/TBV Ratio | -2.21 |
| P/FCF Ratio | -2.23 |
| P/OCF Ratio | -2.22 |
Financial Position
Vor Biopharma Inc. maintains a current ratio of 31.15, meaning it holds 31.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 31.15 |
| Quick Ratio | 30.57 |
| Debt / Equity | -1.95 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -286.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 88.37 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Vor Biopharma Inc.'s stock has gained approximately 203.386% over the past 52 weeks. The 50-day moving average sits at 15.15, while the 200-day moving average is 19.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | 203.386% |
| 50-Day Moving Average | 15.15 |
| 200-Day Moving Average | 19.58 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -371.42M, while operating income came in at -373.51M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -373.51M |
| Pretax Income | -883.08M |
| Net Income | -883.08M |
| EBITDA | -371.42M |
| EBIT | -373.51M |
| Earnings Per Share (EPS) | -47.34 |
Balance Sheet
Vor Biopharma Inc. holds 491.53M in cash and equivalents against 2.94M in total debt, resulting in a net debt position of -169.87M. Total book value stands at -1.37B, with working capital of 484.70M providing operational flexibility.
| Cash & Cash Equivalents | 491.53M |
| Total Debt | 2.94M |
| Net Debt | -169.87M |
| Equity (Book Value) | -1.37B |
| Book Value Per Share | -73.59 |
| Working Capital | 484.70M |
Cash Flow
Vor Biopharma Inc. produced -149.89M in operating cash flow over the past twelve months. After subtracting -758,000.00 in capital expenditures, free cash flow totaled -150.65M - equivalent to -8.08 per share.
| Operating Cash Flow | -149.89M |
| Capital Expenditures | -758,000.00 |
| Free Cash Flow | -150.65M |
| FCF Per Share | -8.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -174.09 |
| FCF Yield | -44.82 |
Stock Splits
Vor Biopharma Inc.'s most recent stock split took place on September 19, 2025 with a 20:1 split ratio.
| Last Split Date | 9/19/2025 |
| Split Ratio | 20:1 |
Scores
Vor Biopharma Inc. posts an Altman Z-Score of -4.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.77 |